

Human Papillomavirus Vaccines (HPV)

Vaccine	Protects against HPV types	Approved for	Ages
HPV2 Cervarix® (GSK)	16 and 18	Females ONLY	9–26 years of age
HPV4 Gardasil® (Merck)	6, 11, 16 and 18	Females & Males	

Whenever possible, the same HPV vaccine product should be used for all doses in the series

Indications for Use and Schedule

- Routinely administer to 11-12 year old males & females
- Males & females 13-26 yrs of age who have not been vaccinated
- May be administered at 9 years of age at the provider's discretion

Recommended Schedule: 0, 1-2, 6 months

- Use recommended schedule dosing intervals for series catch-up
- If doses are given using other intervals, assure that minimum intervals have been met
 - 4 weeks between dose 1 & 2
 - 12 weeks between dose 2 & 3
 - 24 weeks between dose 1 & 3

Vaccine Administration

- Intramuscular injection in the deltoid of the arm or anterolateral thigh
- 1-1.5 inch needle 22-25 gauge
- Use professional judgment when selecting needle length
- Can be given simultaneously with other vaccines

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8°C)
- Do NOT freeze
- Keep in the original box
- Shake well before use



Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine.

SPECIAL SITUATIONS

Vaccine Schedule

- Persons turning 27 years of age after the first dose of HPV was administered but before the third dose is given can complete the series using the recommended intervals between doses, even if this means that the series is completed after 27 years of age

Sexual History

- The best way to be sure that a person gets the most benefit from HPV vaccination is to complete all three doses before sexual activity begins. However, sexually active persons 9 through 26 years of age can be vaccinated.
- Females currently taking hormonal contraceptive measures or breast feeding can be vaccinated

Vaccine can be given to those with:

- Genital warts
- Breast feeding
- Immunosuppression- response to vaccine may be diminished
- A positive HPV test
- An equivocal or abnormal Pap test

CONTRAINDICATIONS

Allergic reaction to a previous dose of HPV vaccine or another component of the vaccine

- HPV4 (Gardasil) is contraindicated for persons with a history of immediate hypersensitivity to yeast
- HPV2 (Cervarix) in prefilled syringes is contraindicated for persons with anaphylactic latex allergy

PRECAUTIONS

Moderate or severe illness

Pregnancy

- Pregnancy testing is not needed before vaccination
- If a woman is pregnant after starting the vaccine series, remaining doses should be delayed until after the pregnancy
- If a vaccine dose has been administered during pregnancy, there is no indication for medical intervention
- Report vaccination of pregnant women to the appropriate registry: HPV4 (Gardasil): 800-986-8999 HPV2 (Cervarix): 888-452-9622

FURTHER POINTS

- HPV types 16 & 18 account for 70% of cervical cancers and types 6 & 11 cause more than 90% of external anogenital warts.
- If the HPV vaccine schedule is interrupted, the series does not need to be restarted
- Due to increased reports of syncope (fainting) in adolescents following vaccination, a 15-20 minute observation period is recommended for adolescents after receiving vaccines
- **New!** There are 2 HPV Vaccine Information Statement (VIS), one for Gardasil and another for Cervarix. Use the VIS that matches the vaccine you are giving. Both HPV VISs, can be found at <http://www.immunize.org/vis/>

For additional information, refer to ACIP Provisional Recommendation for HPV Vaccine, MMWR: Quadrivalent HPV Vaccine, Recommendations of the ACIP, March 23, 2007, Catch-up Immunization Schedule for Persons Aged 4 Months–18 Years Who Start Late or Who Are More Than 1 Month Behind and VFC program resolutions located at www.cdc.gov/vaccines.

Adapted from the Michigan Department of Community Health

January 2012